Is a 1% Benefit Really Practice-Changing? ++++ +++ ++ +++

Featured Commentaries Is a 1% Benefit Really Practice-Changing? https://www.medscape.com/viewarticle/esmo-2025-cutting-through-hype-real-data-and-real-math-2025a1000y0e?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 Black Coffee and Cancer Hype Unsubstantiated https://www.medscape.com/viewarticle/black-coffee-and-cancer-hype-unsubstantiated-2025a1000y6o?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 The Next Frontier in Breast Reconstruction? https://www.medscape.com/viewarticle/sensation-must-be-next-frontier-breast-reconstruction-2025a1000y6m?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 Does Treatment Timing Affect Chemoradiation Response? https://www.medscape.com/viewarticle/circadian-rhythm-chemoradiation-does-treatment-timing-affect-2025a1000vzv?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 ESMO: Neoadjuvant Combo Confirms EFS Edge in Melanoma https://www.medscape.com/viewarticle/esmo-neoadjuvant-combo-confirms-event-free-survival-edge-2025a1000yeu?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 AI Mining Patient Messages for Cancer Research https://www.medscape.com/viewarticle/can-ai-use-patient-messages-identify-new-cancer-care-2025a1000wak?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 Cardiotoxicity Risk Lingers for Cancer Survivors https://www.medscape.com/viewarticle/cardiotoxicity-risk-lingers-cancer-survivors-2025a1000uy4?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 Also of Interest US Advanced Breast Cancer Survival Up, Global Progress Lags https://www.medscape.com/viewarticle/us-advanced-breast-cancer-survival-global-progress-lags-2025a1000vup?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 US Advanced Breast Cancer Survival Up, Global Progress Lags Will Pass HER3-DXd Active Against Metastatic Breast Cancer, Brain Metastases https://www.medscape.com/viewarticle/patritumab-deruxtecan-clinically-active-against-metastatic-2025a1000uo5?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 Patritumab Deruxtecan Clinically Active Against Metastatic Breast Cancer and Brain Metastases Edited by Vineeta Teotia US Drug Spotlight Eculizumab https://reference.medscape.com/drug/soliris-bkemv-eculizumab-342875?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 Cladribine https://reference.medscape.com/drug/mavenclad-cladribine-342213?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 Vismodegib https://reference.medscape.com/drug/erivedge-vismodegib-999716?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818 Indicated for treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation